Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
142 hedge funds and large institutions have $2.38B invested in Soleno Therapeutics in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 14 closing their positions.
200% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 14
104% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 28
85% more call options, than puts
Call options by funds: $44.5M | Put options by funds: $24M
33% more capital invested
Capital invested by funds: $1.79B → $2.38B (+$589M)
25% more funds holding
Funds holding: 114 → 142 (+28)
0.75% more ownership
Funds ownership: 120.48% → 121.22% (+0.75%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$46.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.8M |
| 3 |
Janus Henderson Group
London,
|
+$34.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.9M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$49.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$29.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$23M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$11.7M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$10.7M |
SLNO Hedge Fund Activity: Q3 2024 in Review
142 of the 6,971 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2024, worth a combined $2.38B — up 33% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SLNO positions and 14 closed out — a net gain of 28 holders — while 57 added to existing stakes and 28 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $46.7M. The largest seller was Vivo Capital, cutting an estimated $49.1M.
- 142 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2024, up from 114 in Q2 2024.
- Funds reported $2.38B of Soleno Therapeutics stock for Q3 2024, up 33% quarter-over-quarter.
- 42 funds opened new Soleno Therapeutics positions in Q3 2024 and 14 closed out, a net change of +28 holders.
- The largest Soleno Therapeutics buyer in Q3 2024 was Alyeska Investment Group, an estimated $46.7M added.
- The largest Soleno Therapeutics seller in Q3 2024 was Vivo Capital, an estimated $49.1M sold.
Based on aggregated 13F filings for Q3 2024.